DYNAVAX AND BIOLOGICAL E ANNOUNCE COMMERCIAL SUPPLY AGREEMENT OF DYNAVAX’S CpG 1018 ADJUVANT FOR BIOLOGICAL E’S COVID-19 VACCINE CANDIDATE

Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, today announced the execution of a commercial supply agreement of Dynavax’s CpG 1018^TM advanced adjuvant, for use in BE’s subunit COVID-19 vaccine candidate, CORBEVAX™. The commercial supply agreement extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, BE expects to commence product launch of CORBEVAX^TMlater this year.

Last month, India’s Union Ministry of Health announced that it had finalized arrangements with BE to reserve 300 million doses of CORBEVAX™ to be manufactured later this year. The arrangement with BE is part of the wider endeavor from the Government of India to encourage indigenous vaccine manufacturers by providing financial support.

Ryan Spencer, Chief Executive Officer of Dynavax commented, “Dynavax is proud to extend our collaboration with Biological E with a commercial supply agreement and deliver significant amounts of CpG 1018 in hopes that CORBEVAX™ will be an important COVID-19 vaccine protecting people globally regardless of income level.”

“We are pleased to collaborate with Dynavax and our collaboration will produce yet another vital vaccine against the spread of COVID-19. We believe CORBEVAX™ will play a critical role in eradicating the global pandemic,” said Ms. Mahima Datla, Managing Director, Biological E. Limited.